Lifshitz Law PLLC Announces Investigations of Cassava Sciences, Inc. (NASDAQ: SAVA), iRhythm Technologies, Inc. (NASDAQ: IRTC), Xponential Fitness, Inc. (NYSE: XPOF), and Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross [Yahoo! Finance]
Cassava Sciences, Inc. (NASDAQ: SAVA) had its price target raised by analysts at HC Wainwright from $124.00 to $131.00. They now have a "buy" rating on the stock.
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam [Yahoo! Finance]
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam